 |
KaloBios to Present at Credit Suisse Antibody Conference
May 8, 2013
|
8.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 8, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) today announced that the company will present at the Credit Suisse Antibody Conference, to be held in New York City on May 10, 2013. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the co...
|
|
KaloBios to Present at Needham Healthcare Conference
Apr 24, 2013
|
9.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., April 24, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company has been selected to present at the 12th Annual Needham Healthcare Conference, to be held in New York City on April 30-May 1, 2013. KaloBios Chief Financial Officer, Jeffrey H. Cooper, will provide an overview ...
|
|
U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios' Novel Biologic Candidate for Pseudomonas aeruginosa
Apr 23, 2013
|
18.4 KB |
|
| |
CHICAGO, April 23, 2013 /PRNewswire/ --
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), and KaloBios Pharmaceuticals (Nasdaq: KBIO) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Sanofi Pasteur for the investigation of KB001A, an antibody f...
|
|
KaloBios' Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
Apr 17, 2013
|
9.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., April 17, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that David Pritchard, President and Chief Executive Officer, will speak at the BIO 2013 International Convention in Chicago, IL on Tuesday, April 23 as part of a panel entitled, "New Defenses Against Old Enemies: Vaccines and Biothera...
|
|
KaloBios to Present at Future Leaders in the Biotech Industry Conference
Apr 1, 2013
|
9.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., April 1, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that the company has been selected to present at the 2013 BioCentury-Thomson Reuters Future Leaders in the Biotech Industry Conference, to be held in New York City on April 5, 2013. KaloBios President and Chief Executive Officer, David...
|
|
KaloBios Announces Fiscal Year 2012 Financial Results
Mar 27, 2013
|
21.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., March 27, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced financial results for fiscal year 2012.
(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)
Financial Highlights ($ in millions, except per share data, unaudited)
...
|
|
KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
Feb 26, 2013
|
49.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) presented data from its Phase 1/2 study in persistent asthma for KB002 (precursor chimeric anti-GM-CSF monoclonal antibody to KB003) at the American Academy of Allergy, Asthma & Immunology (AAAI) Annual Meeting in Austin, Texas. The findings dem...
|
|
KaloBios Pharmaceuticals Completes Initial Public Offering
Feb 7, 2013
|
7.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) today announced the completion of its initial public offering of 8,750,000 shares of common stock at $8.00 per share. Gross proceeds from the offering were $70 million, and net proceeds were approximately $62 million, after deducting the underwrit...
|
|
KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
Jan 31, 2013
|
7.5 KB |
|
| |
SOUTH SAN FRANCISCO, CA (January 31, 2013): KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) today announced the pricing of its previously announced initial public offering of 8,750,000 shares of common stock at a price to the public of $8.00 per share, less underwriting discounts and commissions. KaloBios has granted the underwriters a 30-...
|
|
KaloBios Initiates Phase 2 Study with KB001-A Humaneered® Monoclonal Antibody in Cystic Fibrosis Patients
Jan 10, 2013
|
11.4 KB |
|
| |
SOUTH SAN FRANCISCO, CA (January 10, 2013): KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB001-A, the company's anti-PcrV Humaneered®, PEGylated monoclonal antibody fragment. The study will investigate the safety and efficacy of intravenously adminis...
|
|
KaloBios Pharmaceuticals Files Registration Statement for Proposed IPO
Oct 5, 2012
|
7.4 KB |
|
| |
SOUTH SAN FRANCISCO, CA (October 5, 2012): KaloBios Pharmaceuticals, Inc. today announced that it filed a Registration Statement with the Securities and Exchange Commission for a Proposed Initial Public Offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.Leer...
|
|
KaloBios Initiates Phase 2 Study with KB003 Humaneered™ Monoclonal Antibody in Severe Asthma
Sep 11, 2012
|
10.9 KB |
|
| |
SOUTH SAN FRANCISCO, CA (September 11, 2012): KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered™ monoclonal antibody, in subjects with severe asthma uncontrolled by corticosteroids.The multi-cen...
|
|
KaloBios Completes Debt Financing of Up to $15 Million - Debt Financing Follows $20.25 Million in Gross Equity Raised in Second Quarter
Sep 6, 2012
|
9.6 KB |
|
| |
SOUTH SAN FRANCISCO, CA (September 6, 2012): KaloBios Pharmaceuticals, Inc. today announced that the company has completed a $10 million long-term debt financing with MidCap Financial SBIC, LP, with an option to borrow an additional $5 million by the end of the second quarter of 2013. The company also noted that, during the second quarter of 2012,...
|
|
Jeff Cooper Joins KaloBios as Chief Financial Officer
Jul 10, 2012
|
9.0 KB |
|
| |
SOUTH SAN FRANCISCO, CA (July 10, 2012) – KaloBios Pharmaceuticals, Inc. KaloBios Pharmaceuticals, Inc. today announced the appointment of Jeffrey H. Cooper as Chief Financial Officer. Mr. Cooper was previously Senior Vice President and Chief Financial Officer of BioMarin Pharmaceutical, Inc., a publicly traded pharmaceutical company....
|
|
KaloBios' KB001 Demonstrates Safety, Potential as New Approach to Preventing Pseudomonas Ventilator Associated Pneumonia
Jun 25, 2012
|
10.7 KB |
|
| |
SOUTH SAN FRANCISCO, CA (June 25, 2012) - Phase 2a trial results with KB001 suggest the recombinant, human PEGylated monoclonal antibody fragment, under development by KaloBios Pharmaceuticals, Inc. and Sanofi Pasteur, offers potential as an alternative to antibiotics for preventing or reducing pneumonias in mechanically ventilated intensive care ...
|
|
KaloBios Appoints Néstor Molfino as Chief Medical Officer
Jun 7, 2012
|
8.5 KB |
|
| |
SOUTH SAN FRANCISCO, CA (June 7, 2012) - KaloBios Pharmaceuticals, Inc. today announced the appointment of Néstor A. Molfino, M.D. as Chief Medical Officer. Dr. Molfino was previously Vice President, Clinical Development and Respiratory Therapeutic Area Head at MedImmune, Inc. (AstraZeneca Biologics)."Néstor Molfino joins KaloBios with...
|
|
KaloBios Initiates Phase 1 Clinical Trial of KB004 in EphA3-Expressing Hematologic Malignancies
Mar 23, 2011
|
10.6 KB |
|
| |
SOUTH SAN FRANCISCO, CA (March 23, 2011) – KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced treatment of the first patient in a Phase 1 clinical trial of KB004, its first-in-class Humaneered™ monoclonal antibody, in EphA3-expressing hematologic malignancies.EphA3 is an onco-fetal prot...
|
|
Anti-Pseudomonas Activity of KaloBios' sanofi pasteur's KB001 May Prevent Serious Lung Infections and Limit Damaging Inflammation
May 17, 2010
|
12.6 KB |
|
| |
SOUTH SAN FRANCISCO, CA (May 17, 2010) – The data from the initial clinical studies with KB001, a novel antibody fragment against PcrV on Pseudomonas aeruginosa (Pa) bioengineered by KaloBios Pharmaceuticals, Inc. and partnered with sanofi pasteur, demonstrated promising therapeutic activity in the prevention of serious lung infection in mecha...
|
|
KaloBios Partners with Sanofi Pasteur on Novel Prevention and Treatment for Pseudomonas aeruginosa
Jan 11, 2010
|
7.1 KB |
|
| |
SOUTH SAN FRANCISCO, CA (January 11, 2010) – KaloBios Pharmaceuticals, Inc. today announced an agreement with Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, for the development and commercialization of KB001, an investigational new biologic for the treatment or prevention of Pseudomonas aeruginosa (Pa) infections. Sanofi Pa...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter